Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Dermatology
Biotech
Almirall signs yes-nonsense deal with Eloxx for $3M upfront
Almirall is handing over $3 million for Eloxx Pharmaceuticals’ molecule for a pair of rare skin diseases just before the drug enters the clinic.
James Waldron
Mar 13, 2024 10:31am
Lilly's lebrikizumab clears eczema in people with skin of color
Mar 11, 2024 9:24am
Incyte's oral Dupixent rival hits in midphase skin disease trial
Mar 11, 2024 7:16am
Medicxi merges 6 dermatology biotechs into one, adds $100M
Feb 11, 2024 7:00pm
Chasing Boehringer, Anaptys hits goal in skin disease phase 3
Oct 9, 2023 9:20am
Bayer-partnered Azitra will use $7.5M IPO to move into clinic
Jun 22, 2023 9:20am